Logo image of DBV.PA

DBV TECHNOLOGIES SA (DBV.PA) Stock Fundamental Analysis

EPA:DBV - Euronext Paris - Matif - FR0010417345 - Common Stock - Currency: EUR

0.812  +0.03 (+3.44%)

Fundamental Rating

3

DBV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. DBV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, DBV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DBV has reported negative net income.
In the past year DBV has reported a negative cash flow from operations.
DBV had negative earnings in each of the past 5 years.
In the past 5 years DBV always reported negative operating cash flow.
DBV.PA Yearly Net Income VS EBIT VS OCF VS FCFDBV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -63.70%, DBV is doing worse than 66.67% of the companies in the same industry.
The Return On Equity of DBV (-91.83%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROIC N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
DBV.PA Yearly ROA, ROE, ROICDBV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

With an excellent Gross Margin value of 95.70%, DBV belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
DBV's Gross Margin has been stable in the last couple of years.
DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
DBV.PA Yearly Profit, Operating, Gross MarginsDBV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.
DBV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DBV has been increased compared to 5 years ago.
The debt/assets ratio for DBV is higher compared to a year ago.
DBV.PA Yearly Shares OutstandingDBV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
DBV.PA Yearly Total Debt VS Total AssetsDBV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

DBV has an Altman-Z score of -1.84. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DBV (-1.84) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.09 indicates that DBV is not too dependend on debt financing.
DBV has a better Debt to Equity ratio (0.09) than 70.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.84
ROIC/WACCN/A
WACC7.37%
DBV.PA Yearly LT Debt VS Equity VS FCFDBV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.29 indicates that DBV has no problem at all paying its short term obligations.
DBV has a better Current ratio (3.29) than 68.06% of its industry peers.
DBV has a Quick Ratio of 3.29. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.29, DBV is in the better half of the industry, outperforming 69.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29
DBV.PA Yearly Current Assets VS Current LiabilitesDBV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.64% over the past year.
Looking at the last year, DBV shows a very strong growth in Revenue. The Revenue has grown by 224.69%.
Measured over the past years, DBV shows a small growth in Revenue. The Revenue has been growing by 0.50% on average per year.
EPS 1Y (TTM)19.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%

3.2 Future

Based on estimates for the next years, DBV will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.96% on average per year.
DBV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 79.69% yearly.
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y14.97%
Revenue Next Year-55.09%
Revenue Next 2Y264.61%
Revenue Next 3Y338.83%
Revenue Next 5Y79.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBV.PA Yearly Revenue VS EstimatesDBV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
DBV.PA Yearly EPS VS EstimatesDBV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBV. In the last year negative earnings were reported.
Also next year DBV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBV.PA Price Earnings VS Forward Price EarningsDBV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBV.PA Per share dataDBV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as DBV's earnings are expected to grow with 59.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.12%
EPS Next 3Y59.71%

More info and screens

0

5. Dividend

5.1 Amount

DBV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA

EPA:DBV (3/7/2025, 7:00:00 PM)

0.812

+0.03 (+3.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)07-28 2025-07-28
Inst Owners29.72%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap16.66M
Analysts82.86
Price Target6.38 (685.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.87%
Min EPS beat(2)-68.32%
Max EPS beat(2)10.57%
EPS beat(4)3
Avg EPS beat(4)13.32%
Min EPS beat(4)-68.32%
Max EPS beat(4)67%
EPS beat(8)6
Avg EPS beat(8)-2.17%
EPS beat(12)8
Avg EPS beat(12)1.62%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-20.42%
Min Revenue beat(2)-29.38%
Max Revenue beat(2)-11.45%
Revenue beat(4)2
Avg Revenue beat(4)690.02%
Min Revenue beat(4)-29.38%
Max Revenue beat(4)2602.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)27.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.15
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.23
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-4.64
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0.71
BVpS3.55
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.7%
ROE -91.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.7%
FCFM N/A
ROA(3y)-48.56%
ROA(5y)-53.59%
ROE(3y)-66.73%
ROE(5y)-73.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.65%
GM growth 5Y1.43%
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 15.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -1.84
F-Score3
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)11.98%
Cap/Sales(5y)19.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.69%
EPS Next Y-36.93%
EPS Next 2Y2.12%
EPS Next 3Y59.71%
EPS Next 5Y14.97%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%-49.52%
Revenue Next Year-55.09%
Revenue Next 2Y264.61%
Revenue Next 3Y338.83%
Revenue Next 5Y79.69%
EBIT growth 1Y20.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y56.49%
EBIT Next 5YN/A
FCF growth 1Y-50.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.06%
OCF growth 3YN/A
OCF growth 5YN/A